Sagimet Biosciences(SGMT) - 2024 Q1 - Quarterly Results
Sagimet Biosciences(SGMT)2024-05-15 20:05
Exhibit 99.1 Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates Denifanstat Phase 2b FASCINATE-2 clinical data to be presented as an oral presentation at the EASL International Liver Congress 2024 taking place in Milan, Italy from June 5-8, 2024 End-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) expected in the second quarter of 2024 Preparations are underway to start a pivotal Phase 3 trial evaluating denifanstat in patients with metabolic dysfu ...